Mynosys Cellular Devices is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enable procedural excellence. Developers of the U.S. and internationally approved Zepto Precision Cataract Surgery platform, the company is committed to developing high-quality solutions to assist physicians in delivering the best care to patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/09/19 | $25,000,000 |
Decheng Capital | undisclosed |
